Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Recommendation of “Hold” from Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a consensus rating of “Hold” by the eight ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $6.75.

Several brokerages have recently issued reports on INO. UBS Group restated an “overweight” rating on shares of Inovio Pharmaceuticals in a research report on Friday, November 14th. Piper Sandler reaffirmed an “overweight” rating and issued a $6.00 price objective (up from $5.00) on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. HC Wainwright reiterated a “neutral” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, December 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a report on Monday, December 29th. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, November 4th.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of large investors have recently bought and sold shares of INO. Janus Henderson Group PLC increased its position in Inovio Pharmaceuticals by 1.3% during the 4th quarter. Janus Henderson Group PLC now owns 3,308,406 shares of the biopharmaceutical company’s stock valued at $5,773,000 after purchasing an additional 42,146 shares during the period. Vanguard Group Inc. lifted its position in Inovio Pharmaceuticals by 35.0% during the third quarter. Vanguard Group Inc. now owns 2,712,872 shares of the biopharmaceutical company’s stock valued at $6,348,000 after acquiring an additional 703,727 shares during the last quarter. Boxer Capital Management LLC purchased a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter valued at $5,382,000. Millennium Management LLC boosted its holdings in Inovio Pharmaceuticals by 468.7% in the third quarter. Millennium Management LLC now owns 1,972,518 shares of the biopharmaceutical company’s stock worth $4,616,000 after acquiring an additional 1,625,653 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Inovio Pharmaceuticals by 40.7% in the 4th quarter. Geode Capital Management LLC now owns 769,356 shares of the biopharmaceutical company’s stock worth $1,340,000 after purchasing an additional 222,609 shares in the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals News Roundup

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: AAII published an explainer on a recent short-term rally (an 8.35% move) that may help investors understand recent momentum and trading drivers. Why Inovio Pharmaceuticals, Inc.’s (INO) Stock Is Up 8.35%
• Neutral Sentiment: Inovio presented at the Oppenheimer Healthcare Life Sciences conference; the transcript is available for investors who want direct management comments on pipeline, regulatory timing and strategy. Review the transcript for any forward-looking detail that could change near-term expectations. Inovio Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
• Negative Sentiment: Multiple law firms have issued notices and several class actions or investigations have been filed alleging securities fraud tied to statements about the company’s business and prospects; firms are soliciting lead plaintiffs and reminding investors of the April 7, 2026 deadline — this raises litigation risk, potential costs, and selling pressure. INO CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Inovio Investors of Securities Class Action Deadline on April 7, 2026
• Negative Sentiment: Several prominent firms (Levi & Korsinsky, Rosen, Bragar Eagel & Squire, Schall, Gross, Holzer & Holzer, Rosen, Frank R. Cruz, etc.) have public notices or filings; one complaint specifically alleges manufacturing issues with the CELLECTRA device and that the INO-3107 BLA and regulatory prospects were overstated — allegations that, if substantiated, could materially affect approval timelines and commercialization. Holzer & Holzer LLC Reminds INO Investors of the April 7, 2026 Lead Plaintiff Deadline
• Negative Sentiment: Critical commentary and analysis (including a cautionary piece suggesting high downside risk) add to negative market sentiment and could reinforce selling pressure among risk-averse investors. Is Inovio Pharmaceuticals Stock Going to $0?

Inovio Pharmaceuticals Stock Performance

INO stock opened at $1.85 on Thursday. The firm has a fifty day moving average price of $1.73 and a 200 day moving average price of $2.06. Inovio Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $2.98. The firm has a market cap of $123.45 million, a PE ratio of -0.71 and a beta of 1.72.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.